Inflammatory Pathways in Ulcerative Colitis

Ulcerative colitis is characterised by chronic inflammation of the colonic mucosa driven by a complex interplay between epithelial barrier dysfunction, dysregulated innate and adaptive immunity, and microbial perturbations. Injury to the epithelium triggers release of damage-associated molecular patterns that engage pattern recognition receptors such as Toll-like receptors on resident macrophages and dendritic cells. This initiates activation of transcription factors, notably NF-κB and STAT3, that orchestrate the induction of pro-inflammatory cytokines including tumour necrosis factor-α, interleukin-1β and interleukin-6. Downstream signalling promotes recruitment and differentiation of effector T helper 17 (Th17) cells, which secrete IL-17 to amplify mucosal damage, while relative deficiency of regulatory T (Treg) cells impairs resolution of inflammation. Activation of the NLRP3 inflammasome further enhances IL-1β maturation, fuelling epithelial apoptosis and barrier breach. Concurrent microbial dysbiosis reduces production of short-chain fatty acids, undermining epithelial homeostasis and Treg function. Overactivation of these pathways underpins mucosal ulceration and systemic symptoms, and constitutes the principal targets of emerging therapies that aim to restore immune balance and barrier integrity.

Research from Nature Portfolio

Recent studies have illuminated the molecular basis of dual transcriptional regulation in colonic inflammation. One investigation demonstrated that administration of a plant-derived phenolic ester significantly attenuated disease activity by concurrently inhibiting NF-κB and STAT3 activation within colonic tissues. This dual blockade reduced expression of pro-survival genes and inflammatory mediators, thereby preserving mucosal architecture and function. Another study explored a dietary flavonoid that suppresses Toll-like receptor-4 signalling and NLRP3 inflammasome assembly in epithelial and immune cells. The flavonoid reduced cytokine release and myeloperoxidase activity, resulting in diminished histological injury and remission of colitis symptoms in preclinical models. Together, these foundational insights validate key nodal points for therapeutic modulation of inflammatory cascades in ulcerative colitis.

Inflammatory Pathways in Ulcerative Colitis publication trend

The graph below shows the total number of articles in inflammatory pathways in ulcerative colitis across all publications each year (not limited to Nature Index journals).

Technical terms

NF-κB: A nuclear transcription factor that regulates expression of pro-inflammatory genes upon activation by cytokines or microbial signals.

STAT3: A signal transducer and activator of transcription that mediates cytokine-driven gene expression linked to cell survival and inflammation.

NLRP3 inflammasome: A multiprotein intracellular complex that promotes maturation and release of IL-1β and IL-18 in response to cellular stress.

T helper 17 (Th17) cell: A subset of CD4+ T lymphocytes characterised by secretion of IL-17 and promotion of tissue inflammation.

Regulatory T (Treg) cell: An immunosuppressive CD4+ T cell subset that secretes IL-10 and TGF-β to maintain immune tolerance and resolve inflammation.

Short-chain fatty acids (SCFAs): Microbial metabolites—primarily acetate, propionate and butyrate—that support epithelial health and Treg differentiation.

References

1. Ginseng-derived nanoparticles alleviate inflammatory bowel disease via the TLR4/MAPK and p62/Nrf2/Keap1 pathways. Journal of Nanobiotechnology (2024).
2. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. Scientific Reports (2017).
3. Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis. Scientific Reports (2016).
4. Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis. Frontiers in Immunology (2021).